Colorectal Cancer: Competitive Landscape to 2026

Colorectal cancer (CRC) is a cancer that originates in either the colon or the rectum. CRC is the fourth leading cause of mortality among cancer patients in the world, and is the third most diagnosed cancer globally. Most cases of CRC present as adenocarcinomas, but other types of CRC include gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, leiomyosarcoma, melanoma, and squamous cell carcinoma.

This report provides an assessment of the pipeline, clinical, and commercial landscape of CRC. Overall, GlobalData expects new drug approvals with noval approaches to treatment to drive the CRC market growth over the next decade (2016–2026).

Scope

GlobalData’s Colorectal Cancer: Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the slide deck include:

Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type

Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

Commercial Assessment—leading marketed products, current and future players

Competitive Landscape Analysis—key market events (2016–2026)

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global CRC market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CRC market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

Roche

Merck

Bristol-Myers Squibb

Regeneron

Amgen

Boehringer Ingelheim

Bayer

Eli Lilly

Array BioPHarma

Taiho Pharmacuetical

Ono Pharmaceutical

Mologen

Symphogen

Sumitomo Dainippon Pharma

DanDrit Biotech

Table of Contents

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 Introduction

3.1 Report Scope

3.2 Events Classification Overview

3.3 Disease Definition & Epidemiology Overview

4 Pipeline Assessment

4.1 Pipeline Overview

4.2 Pipeline Breakdown by Region/Country

4.3 Pipeline Breakdown by Molecule Type and Target

4.4 Drug Review Designations

4.5 Products in Clinical Development

5 Clinical Trial Assessment

5.1 Clinical Trials Overview

5.2 Top Sponors of Clinical Trials in CRC

5.3 Trial Breakdown by Region

5.4 Trial Success Rate

5.5 Therapy Area Perspective

5.6 Enrollment Analytics

6 Commercial Assessment

6.1 Leading Marketed Products

6.2 Current & Future Players

7 Competitive Landscape Analysis (2016–2026)

7.1 US

7.2 5EU

7.3 Japan

7.4 China

8 Appendix

8.1 Sources

8.2 Methodology

8.3 Key Events Included in the Analysis

8.4 About the Authors

8.5 About GlobalData

8.6 Disclaimer

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports